Commonwealth Coat of Arms of Australia

 

Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 1) 2020

I, Renaye Lucchese, delegate of the Minister for Health, make the following Determination.

Dated  23 March 2020   

Renaye Lucchese

Acting Assistant Secretary

Diagnostic Imaging and Pathology Branch

Medical Benefits Division

Health Financing Group

Department of Health

 

 

 

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1— Amendments

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018

 

1  Name

  This instrument is the Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 1) 2020

2  Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 April 2020

 

 Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1— Amendments

 

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018

1 Schedule 1 (item 73336, column 2)

Omit “dabrafenib or vemurafenib”, substitute “dabrafenib, vemurafenib or encorafenib